Transcriptional and Posttranscriptional Regulation of Fibulin-1 by Estrogens Leads to Differential Induction of Messenger Ribonucleic Acid Variants in Ovarian and Breast Cancer Cells
- 1 February 2005
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 146 (2) , 760-768
- https://doi.org/10.1210/en.2004-1239
Abstract
Fibulin-1 is an extracellular matrix protein overexpressed in epithelial ovarian and breast cancers. In estrogen receptor (ER)-positive ovarian and breast cancer cell lines, fibulin-1 mRNA levels are markedly increased by estrogens. Transfection experiments using fibulin-1 promoter constructs indicate that 17beta-estradiol (E2) increases fibulin-1 gene transcription and that ERalpha is more potent than ERbeta to mediate E2 regulation of the transfected fibulin-1 promoter. Using SL2 cells devoid of specificity protein 1 (Sp1) and site-directed mutagenesis of GC boxes, we evidenced that the E2 regulation occurs through a proximal specificity protein 1 binding site. In addition, we show that fibulin-1C and -1D mRNAs, the two major fibulin-1 splicing variants, are differentially induced by E2. The induction of both mRNAs variants is direct and independent of a newly synthesized protein intermediate. Interestingly, actinomycin D chase experiments demonstrate that E2 treatment selectively shortens the fibulin-1D mRNA half-life. This indicates that estrogens affect differentially the stability of fibulin-1 variants and may explain the lower accumulation of fibulin-1D mRNA on E2 treatment. In conclusion, our data show that estrogens, via ERalpha, are key regulators of fibulin-1 expression at both the transcriptional and posttranscriptional levels. The preferential induction of the fibulin-1C variant, which is overexpressed in ovarian and breast cancer, might play an important role in estrogen-promoted carcinogenesis.Keywords
This publication has 58 references indexed in Scilit:
- Estrogen Replacement Therapy and Ovarian CancerEpidemiology, 2004
- Breast cancer and hormone-replacement therapy: the Million Women StudyPublished by Elsevier ,2003
- Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic ProceduresThe Women's Health Initiative Randomized TrialJAMA, 2003
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal WomenJAMA, 2003
- Postmenopausal Hormone Replacement TherapyJAMA, 2002
- Menopausal Hormone Replacement Therapy and Risk of Ovarian CancerJAMA, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US WomenJAMA, 2001
- A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancerJournal of Clinical Epidemiology, 2000
- Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-ANature, 1986